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All cases of malignant melanoma diagnosed in 23 hospi-
tals in Catalonia, from 2000 to 2007 were recorded and 
melanoma incidence calculated and adjusted for the Eu-
ropean standard population via the direct method. The 
age standardised rate/100,000 inhabitants varied from 
6.74 in 2000 to 8.64 in 2007 for all melanomas and from 
4.79 to 5.80 for invasive melanomas; the Breslow thick-
ness was stable during the period. The increase in inva-
sive melanoma incidence in the elderly was remarkable, 
the crude rate/100,000 inhabitants increasing from 11.04 
(2000) to 15.49 (2007) in the 60–64 year population, whi-
le remaining more stable in the 30–34 year range, from 
3.97 in 2000 to 4.55 in 2007, and with a tendency to de-
crease from 5.1 in 2000 to 2.5 in 2007 for the age range of 
25–29 years. These lower age ranges are much more af-
fected by immigration. Despite the large immigrant po-
pulation (nearly one million immigrants arrived in Cata-
lonia during the study period from countries with a low 
melanoma incidence), melanoma incidence in our region 
has risen considerably and this trend is likely to persist 
in the near future. Key words: malignant melanoma; hos-
pital based registry; incidence; epidemiology; skin cancer.
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The incidence of cutaneous malignant melanoma (CMM) 
has increased in recent decades more than any other ma-
lignant neoplasm (1, 2). In the United States, the number 
of melanomas diagnosed has increased by 619% and the 
mortality has increased 165% between 1950 and 2000 
(2). The highest incidence rates of CMM are observed in 
Australia and New Zealand followed by North America 
and Northern Europe (1, 3–5).
The incidence and mortality of melanoma in people 
living in Europe vary considerably between countries 
(6), the highest incidence rates being in northern and 
western countries and the lowest in southern countries 
(1). These variations are likely to be linked to specific 
behaviour (winter holidays, sun-seeking behaviour) 
as well as prevalent skin phototype and other clinical 
characteristics of the population such as the number of 
naevi or the prevalence of red hair (7). Some regions 
have reported a declining trend in melanoma incidence, 
whilst for others the rise in incidence persists (8, 9).
Spain has one of Europe’s lowest incidence and mor-
tality rates. Although there are only a few studies on the 
epidemiology of melanoma in Spain, an increase in inci-
dence over the past decades has also been reported (10). 
Our region of study is Catalonia, located in the 
North-eastern part of Spain. In Catalonia only 2 cancer 
population registries exist, which together covered a 
population of 1,174,977 in 2001, representing only 19% 
of the total Catalan population living in an area far away 
from the city of Barcelona and most populated cities of 
the region. According to these registries, over the past 
20 years, CMM incidence has increased substantially at 
a faster rate than any other neoplasm in Catalonia (11). 
Marcos-Gragera et al. (11), suggested that this trend will 
probably continue for the next few years. Nevertheless, 
CMM mortality trends have already been published, the 
crude rate between 2000–2004 being 2.52 for men and 
2.11 for women and for 2005–2009 being 2.72 for men 
and 2.28 for women (crude rates per 100,000 person-
years). On the contrary, epidemiological data from other 
regions of Spain suggest that melanoma mortality rates 
have been decreasing over the past 10 years, at least in 
males (12).
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A study performed in one hospital from our region 
reported an increase in the incidence of both in situ and 
invasive melanomas. Among the invasive melanomas not 
only thin melanomas increased, but also thick ones with a 
resulting stable mean Breslow thickness of 1.9 mm (13).
Knowledge of the overall incidence of melanoma in 
our region is crucial for public health care organisation. 
Furthermore, the knowledge of the distribution according 
to Breslow thickness, age, gender, subtype of melanoma 
or localisation would help to establish adequate preven-
tive or early detection policies for targeted populations. 
Rationale
To perform a hospital-based registry of melanoma 
encompassing all Catalonia in order to describe the 
incidence of in situ and invasive melanomas diagnosed 
over an 8-year period (2000–2007) and their clinico-
pathological characteristics.
METHODS
Twenty-three hospitals covering most of the population of Catalo-
nia, 7 million inhabitants, reported the melanoma cases diagnosed 
from 2000 to 2007. Five of the hospitals were tertiary-care hospi-
tals located in Barcelona and its suburbs. The remaining hospitals 
were community-based hospitals and one private hospital. 
Data collected included date of birth, gender, date of diagno-
sis, location of the melanoma, histopathological subtype, Clark 
Index, Breslow thickness and presence of ulceration. 
Data was collected from the melanoma-unit’s databases when 
available (Hospital Clinic de Barcelona, Hospital de Bellvitge 
and Hospital Germans Trias I Pujol). For the remaining hospi-
tals, data was retrospectively collected for the first 5-year period 
(2000–2004), and prospectively for the period 2005–2007.
Statistical analysis
Incidence rates were age-standardised via the direct method 
using the European standard population. Categorical variables 
compared by means of the χ2-test, or the Fisher’s exact test, when 
the expected observations were < 5. For continuous variables, 
mean and standard deviation (SD) were reported. The Student 
t-test was used to compare means between males and females. 
Two-way ANOVA tests were conducted in order to detect dif-
ferences in means of age and Breslow thickness over time. Sta-
tistical analyses were performed with SPSS 10.0 and STATA10.
RESULTS
A total of 5,407 cases were reported in the 8-year study 
period (2000–2007); 408 cases were reported by more than 
one centre and thus duplicated. In all these cases one of 
the entries was eliminated. Ultimately, 4,999 melanoma 
patients were included in the study of which 4,850 pa-
tients were included in the calculation of incidence rates 
because the age at diagnosis and the year of diagnosis was 
known. One third (33%) of cases were reported by one 
referral centre in Barcelona (Hospital Clinic Barcelona) 
and 26% were reported by the other 2 referral hospitals in 
Barcelona’s suburbs (Hospital de Bellvitge and Hospital 
Germans Trias I Pujol) together. In 3,884 cases the mela-
noma was invasive and the remaining 1,125 were in situ. 
Females had 2,748 cases of melanoma (55%), whereas 
men had 2,216 cases (44.3%). In 35 cases, gender data 
was not available. An increasing trend in the number of 
incident cases of melanoma was observed throughout the 
study period (481 cases in 2000; 610 in 2001; 581 in 2002; 
541 in 2003; 551 in 2004; 692 in 2005; 668 in 2006 and 
726 in 2007) (Table I). The total crude rate for melanoma 
(including in situ) per 100,000 inhabitants increased from 
7.74 in 2000 to 10.13 in 2007 and the age standardised 
rate/100,000 inhabitants for the European population 
increased from 6.74 in 2000 to 8.64 in 2007 (Table I). 
For invasive melanomas the total crude rate/100,000 
inhabitants increased from 5.42 in 2000 to 6.77 in 2007 
and the age standardised invasive melanoma rate/100,000 
inhabitants for the European population increased from 
4.79 in 2000 to 5.8 in 2007 (Table I). Crude rates and age 
adjusted for European population rates increased in both 
sexes (Table II). Detail of rates according to age and years 
(2000 to 2007) are detailed in Table SI1 and Fig. S11.
The majority of melanomas were located on the trunk 
(37.5%) followed by lower extremities (20.1%), upper 
extremities (11.7%), face (11.4%), palms and soles 
(7.8%), head and neck (5.1%) and mucosa (1%). The 
location was not properly reported in 5.4% of tumours. 
Histopathological characteristics
The most frequent histopathological subtype was superfi-
cial spreading melanoma (SSM) which represented 59.5% 
Table I. Incidence of melanoma (including in situ melanoma) and 
invasive melanoma
Year
Cases 
n
Population 
in Catalonia
Crude 
ratea
Age 
standar-
d i seda,b
Truncateda  
(35–64 
years)
Cumulative 
(0–74 
years)
Melanoma (including in situ melanoma)
2000 481 6,213,904 7.74 6.74 9.94 0.517%
2001 610 6,305,080 9.67 8.39 12.79 0.694%
2002 581 6,442,797 9.02 7.87 12.70 0.631%
2003 541 6,590,233 8.21 7.02 10.34 0.564%
2004 551 6,727,680 8.19 7.03 10.87 0.555%
2005 692 6,873,649 10.07 8.66 12.93 0.723%
2006 668 7,020,207 9.52 8.17 11.44 0.684%
2007 726 7,168,354 10.13 8.64 13.41 0.709%
Invasive melanoma
2000 337 6,213,904 5.42 4.79 7.29 0.369%
2001 421 6,305,080 6.68 5.85 9.08 0.488%
2002 391 6,442,797 6.07 5.33 8.85 0.426%
2003 341 6,590,233 5.17 4.43 6.57 0.353%
2004 371 6,726,395 5.52 4.77 7.32 0.382%
2005 461 6,873,649 6.71 5.80 8.63 0.487%
2006 443 7,020,207 6.31 5.40 7.82 0.445%
2007 485 7,168,354 6.77 5.80 9.06 0.473%
aRates reported per 100,000 subjects.
bStandardised using the European standard population, Source: 1991 World 
Health Annual of Statistics – based on J Waterhouse et al, Cancer Incidence 
in Five Continents, Lyon, IARC, 1976 (Vol, 3, page 456).
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of tumours, followed by nodular melanoma (NM) (11.7%), 
lentigo maligna melanoma (LMM) (8.4%) and acral lenti-
ginous melanoma (ALM) (4.4%). In 11.4% of melanomas, 
the histopathological subtype was not reported and in 
2.6% it was unclassifiable. The rare melanoma subtypes 
found were lentiginous melanoma of the mucosa (0.5%), 
desmoplastic (0.3%) and Spitzoid melanoma (0.2%).
The Clark level was not reported in 11.3% of the cases. 
In situ melanomas represented 25.5% of the tumours, 
Clark II 15.6%, Clark III 30.0%, Clark IV 17.3% and Clark 
V 3.6%. During the 8 years of the registry, the incidence 
of in situ melanomas remained stable (p = 0.12) (Fig. 1). 
The distribution of melanomas according to Breslow 
thickness also remained stable during the study (data 
not shown). Mean Breslow thickness remained stable 
throughout the study period (p = 0.222) (Fig. S2a1) 
while mean age at diagnosis increased during the period 
(p < 0.001) (Fig. S2b1). Only 13% of cases were reported 
as ulcerated, but the presence/absence of ulceration was 
not reported in 24% of cases. 
The mean age at diagnosis varied according to the 
histopathological subtype and was lower in SSM (mean 
52.6 years) and Spitzoid melanomas (mean 50.6 years) 
compared to NM (mean 59.3 years), ALM (mean 63.01 
years), mucosal MM (62.4 mean years) and LMM (70.3 
mean years) (p < 0 .01). 
Trends by sex
As previously described in other populations, location 
of the melanoma differed significantly between Catalan 
women and men (p < 0.000) (Table III). The trunk was 
the most frequent location in males (48.9%) followed 
by the face (11.4%). In females the trunk represented 
28.5% of cases followed by, almost in equal proportion, 
the lower extremities 28.3%, then upper extremities 
(13.4%) and face (10.9%).
The mean Breslow also differed, being thicker in men 
(mean 2.3, SD 3.21) than women (mean 1.8, SD 3.1) 
(p < 0.001). 
Men were diagnosed at an older age (mean 57.7 
years, SD 16.9) than women (mean 54.3 years, SD 17.9) 
(p < 0.01) (see Fig. S31). An increase in incidence was 
observed in both sexes. 
Trends by subtype and age
The most frequent subtype of melanoma observed 
throughout the study period was SSM in patients aged 
between 50–55 years. However, an increase in LMM 
was also detected among the elderly, usually in their 
seventies.
DISCUSSION
The incidence of melanoma has been increasing world-
wide (1) but with differences according to the charac-
teristics of the population living in a given country 
(skin type, red hair, etc), sunlight incidence during the 
year and sun-exposure behaviour (9, 14). Other factors 
such as the Mediterranean diet were also reported as a 
modifying factor of melanoma incidence (15).
Ribes et al. (16) performed a melanoma incidence pro-
jection in Catalonia for the period 2005–2019. Bayesian 
Table II. Melanoma incidence by sex
Year
Cases 
n
Population 
in Catalonia
Crude 
ratea
Age 
stan dar-
diseda,b
Truncateda 
(35–64 
years)
Cumulative 
(0–74 
years)
Males
2000 195 3,037,429 6.42 5.69 8.09 0.440%
2001 245 3,088,541 7.93 7.04 10.20 0.596%
2002 253 3,164,113 8.00 7.17 10.44 0.561%
2003 263 3,242,996 8.11 7.12 9.63 0.570%
2004 241 3,316,066 7.27 6.40 9.56 0.506%
2005 324 3,396,257 9.54 8.52 11.34 0.744%
2006 307 3,473,240 8.84 7.71 9.57 0.662%
2007 331 3,550,658 9.32 8.33 12.08 0.699%
Females
2000 286 3,176,475 9.00 7.86 11.75 0.599%
2001 363 3,216,539 11.29 9.77 15.35 0.787%
2002 327 3,278,684 9.97 8.68 14.93 0.698%
2003 278 3,347,237 8.31 7.10 11.05 0.566%
2004 309 3,411,315 9.06 7.74 12.18 0.606%
2005 366 3,477,392 10.53 8.90 14.47 0.713%
2006 359 3,546,967 10.12 8.70 13.13 0.710%
2007 391 3,617,696 10.81 9.04 14.56 0.723%
aRates reported per 100,000 subjects.
bStandardised using the European standard population. Source: 1991 World 
Health Annual of Statistics - based on J Waterhouse et al. Cancer Incidence 
in Five Continents, Lyon, IARC, 1976 (Vol. 3, page 456).
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-1997
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Fig. 1. Distribution of in situ melanoma (dark grey) and invasive melanoma 
(light grey) during the 8-year period of the study. The proportion of in situ 
melanomas remained stable (p = 0.12).
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age-period-cohort models were fitted to age-specific 
rates for 1985–2004 to obtain the expected number of 
cases for the 5-year periods 2005–2009, 2010–2014 and 
2015–2019. They estimated 307 new melanoma cases per 
year in men and 478 in women in the period 2005–2009 
with a crude rate/100,000 inhabitants of 10.43 in men 
and 15.57 in women and a world age standardised rate 
of 8.31 in men and 13.21 in women.
Our results confirm that melanoma has been rising con-
siderably among men and women in Catalonia over the 
past decade and that this trend is likely to persist in the near 
future, as suggested by Ribes et al. (16). The incident cases 
that we reported are similar to those estimated by Ribes et 
al., while the crude and age standardised rates were lower 
than expected according to their study. The immigrant 
population settling in Catalonia has grown significantly in 
the past decade (Table SI1). From representing only 2.9% 
of the total population in Catalonia in 2000, growing to 
13.1% in 2006 and reaching 16.4% in 2010. They originate 
mainly from countries with a pigmented skin population 
and/or low melanoma incidence (Table SII1). Among the 
different nationalities, the most frequent are: Moroccans 
(19.6%), Rumanians (8%), Ecuadorians (6%) and Bolivi-
ans (4.7%) (http://www10.gencat.cat/gencat/AppJava/es/
actualitat2/2010/dadesimmigraciacatalunya.jsp). 
One may hypothesise that the increasing number of new 
melanoma cases that we have observed has been diluted 
by the million immigrants that arrived in Catalonia during 
this period. In favour of this hypothesis is the fact that 
crude rates per 100,000 inhabitants for invasive melanoma 
incidence increased from 11.04 in 2000 to 15.49 in 2007 
for the 60–64 year population, an age range less affected 
by immigration, while the crude rate/100,000 inhabitants 
remained more stable from 3.97 in 2000 to 4.55 in 2007 for 
the 30–34 year old group or with a tendency to decrease 
from 5.1 in 2000 to 2.5 in 2007 for the 25–29-year-olds 
(Table SI1 and Fig. S11), much more affected by immigra-
tion (as usually it is young people that migrate for work 
reasons as reflected in Table SI1). 
Another interesting observation from our study is the 
already known fact that Catalan women develop mela-
noma at an earlier age and that they are affected at different 
sites of the body compared with men. Melanoma appears 
mostly on the trunk in men, but in women it affects trunk 
and lower limbs in almost equal proportions. The reason 
why legs are commonly affected in women, but not in 
men, is unknown but is similar in different populations. 
Other epidemiological studies of melanoma performed 
in central and northern Italy, where the climate and skin 
phototypes are similar to Catalonia, reveals that women 
are much more prone to develop melanoma on legs 
compared to men. The possible effect of intermittent sun 
exposure according to different dress in women (i.e. use 
of skirts or shorts) has been suggested as responsible for 
this increase in melanoma incidence on women’s legs 
but this is probably not the main reason and other causes 
may be argued such as the genetic background of different 
subtypes of melanoma influenced by gender.
It is noteworthy that, although the number of cases 
of melanoma in Catalonia was higher in women, the 
incidence increased in similar proportion in both sexes. 
A reason why melanoma is diagnosed at an earlier age in 
women than men may be that women seek medical atten-
tion for skin conditions sooner than men but also may be 
related to the location of the tumour, more visible on lower 
limbs than on the trunk or especially on the back. This may 
also explain why the Breslow index was lower in women 
than men, as melanomas were detected at earlier stages. 
Unfortunately, mean Breslow thickness does not decrease 
during the follow-up period and we have not observed 
an increase in the proportion of in situ melanoma even 
though physicians are now more aware and prepared to 
detect melanoma at earlier stages, suggesting that popula-
tion based strategies for secondary prevention should be 
improved or implemented in our region. 
Our mean age standardised incidence rate/100,000 
inhabitants of 5.27 for invasive melanoma is lower 
than the finding by Crocetti et al. (17) who reported 
that the standardised incidence rate/100,000 inhabitants 
for invasive melanoma rose from 6.4 in 1985–1989 
to 13.6 in 2000–2004 in central Italy. Pellacani et al. 
(18) in northern Italy showed a standardised incidence 
rate/100,000 inhabitants of 9.7 for invasive melanomas 
and 11.9 when also considering in situ ones. However, 
when including in situ melanomas, our standardised 
incidence rate/100,000 inhabitants rose to 7.8. As nearly 
20% of Catalan people have private insurance (http://
www.csbcn.org/area_prov/doblecob_CSB.pdf) and this 
study was neither focused on private dermatologists nor 
private pathologists, any thin melanomas diagnosed in 
private practice and not sent to the referral hospital for 
treatment may have been lost. Taken together, these fin-
dings suggest that melanoma is rising in Catalonia, as in 
other Mediterranean countries, with a trend of increased 
mean age at diagnosis, an increase in in situ melanoma, 
but stable mean Breslow thickness with a possible di-
lution effect of new melanoma cases by immigration 
from low incidence melanoma countries – as it has been 
Table III. Breslow thickness, age at diagnosis and distribution of 
body site according to sex
Total Men Women p
Breslow, mean (SD)   2.02 (3.18)   2.28 (3.29) 1.80 (3.09) 0.000
Age at diagnosis, 
mean (SD) 55.84 (17.51) 57.70 (16.90) 54.29 (17.84) 0.000
Body site, n (%)
Acral 388 (7.8) 140 (6.3) 248 (9) < 0.000
Lower extr. 1,004 (20.1) 216 (9.7) 779 (28.3)
Upper extr. 584 (11.7) 210 (9.5) 369 (13.4)
Head and neck 253 (5.1) 158 (7.1) 91 (3.3)
Face 571 (11.4) 269 (12.1) 300 (10.9)
Trunk 1,876 (37.5) 1,083 (48.9) 783 (28.5)
Mucosal 49 (1) 14 (0.6) 34 (1.2)
Other 200 (4) 89 (4) 108 (3.9)
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recently reported in Australia (19) – suggesting that we 
should also register the origin of the patient as well as 
racial and cultural characteristics. 
One limitation and possible bias of our study is that 
information was partially gathered retrospectively before 
2005 and prospectively thereafter. However, it is the 
largest epidemiological melanoma study performed in 
Catalonia to date. 
Melanoma incidence has risen significantly in the 
Mediterranean countries over the past decade and should 
be considered a public health care problem. Our findings 
may help to establish primary and secondary preventive 
measures aimed at a targeted risk-population. Further 
efforts are required to increase melanoma awareness 
in the general population and the importance of early 
detection among the medical community if we want this 
increasing trend in incidence to stop.
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